Figure 4.

Therapeutic effects of CPMV-1V209, CCMV-1V209, and Qβ-1V209 particles in the in vivo B16F10 melanoma model. (A) Timeline of B16F10 cell inoculation and intratumoral particle injections. (B) Tumor growth curves. Blue arrows indicate the treatment days. (C) Volumetric scatter plot of individual tumors on day 28. Data are means ± SEM (n = 5). The results were compared by one-way ANOVA with Tukey’s multiple comparisons test (***P < 0.001 and **P < 0.01). (D) Survival rates of tumor-bearing mice over 70 days (dashed lines show the intersection with median survival for each treatment). The results were compared using the log-rank (Mantel–Cox) test (*P < 0.05). (All the groups were treated at the same time; therefore, there is only one PBS group. For clarity, we arranged the graphs by VNP/VLP formulation.)